A detailed history of Caxton Associates LP transactions in Incyte Corp stock. As of the latest transaction made, Caxton Associates LP holds 29,696 shares of INCY stock, worth $2.13 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
29,696
Previous 28,181 5.38%
Holding current value
$2.13 Million
Previous $1.71 Million 14.87%
% of portfolio
0.07%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $86,854 - $103,944
1,515 Added 5.38%
29,696 $1.96 Million
Q1 2024

May 15, 2024

SELL
$56.55 - $66.59 $1.11 Million - $1.31 Million
-19,636 Reduced 41.06%
28,181 $1.61 Million
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $628,537 - $717,318
10,880 Added 29.46%
47,817 $2.76 Million
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $1.78 Million - $2.2 Million
29,195 Added 377.1%
36,937 $2.3 Million
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $543,720 - $665,889
7,742 New
7,742 $559,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $679,337 - $850,557
10,265 New
10,265 $684,000
Q3 2020

Nov 16, 2020

SELL
$85.07 - $109.69 $231,730 - $298,795
-2,724 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$74.18 - $108.93 $202,066 - $296,725
2,724 New
2,724 $283,000
Q2 2019

Aug 14, 2019

SELL
$73.52 - $88.7 $7.33 Million - $8.84 Million
-99,713 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$63.56 - $88.17 $6.34 Million - $8.79 Million
99,713 New
99,713 $8.57 Million
Q4 2017

Feb 14, 2018

SELL
$93.56 - $116.6 $205,832 - $256,520
-2,200 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $240,130 - $304,194
2,200
2,200 $257,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.